Vanda Pharmaceuticals Inc. (VNDA)

Market Cap	322.63M
Revenue (ttm)	203.47M
Net Income (ttm)	-66.94M
Shares Out	59.09M
EPS (ttm)	-1.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	557,443
Open	5.32
Previous Close	5.32
Day's Range	5.29 - 5.59
52-Week Range	3.81 - 5.59
Beta	0.74
Analysts	Strong Buy
Price Target	16.50 (+202.2%)
Earnings Date	Nov 5, 2025

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 12, 2006
• Employees: 368
• Stock Exchange: NASDAQ
• Ticker Symbol: VNDA
• Website: https://www.vandapharma.com

Analyst Summary

According to 2 analysts, the average rating for VNDA stock is "Strong Buy." The 12-month stock price target is $16.5, which is an increase of 202.20% from the latest price.

Price Target

$16.5

(202.20% upside)

Analyst Consensus: Strong Buy